In women’s cancers, resistance to a key breast cancer drug is linked to tumor layout
Breast, ovarian and uterine cancerPart of a story we are following · 11 articles · See every update
Researchers have identified patterns linked to a strong breast cancer drug working well in some tumors and stalling in others, a finding relevant to women’s cancers. In a study of tumor samples from patients with metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd), tumors that resisted the drug showed different patterns in gene activity and in how far cancer cells sat from blood vessels.
This does not change anyone’s treatment today. What it gives scientists is a map of where to look next, and that is how better options usually start.
How the study worked
The team took tumor samples from patients treated with T-DXd and used a technique called spatial transcriptomics, which reads which genes are active in each small spot of a tumor and keeps track of where that spot sits. They also looked at some patients’ tumors before treatment and again after the cancer began to grow, and the study was published in Cell Reports Medicine on November 20, 2026. Parts of the work were exploratory, so the findings point to candidate explanations that still need to be tested in more studies.
What is T-DXd and why does location matter?
T-DXd is a type of drug called an antibody-drug conjugate. Think of a delivery truck. The antibody part finds a protein called HER2 on the surface of cancer cells. It then drops off a chemotherapy “payload” at that address.
The drug is used for breast cancers with a lot of HER2 (called HER2-positive) and for those with a small amount (called HER2-low). It works well in both. But some tumors respond much better than others, and until now it was not clear why.
That is where location comes in. A tumor is not one uniform lump. It is a neighborhood, with streets (blood vessels), houses (cancer cells) and local workers (enzymes). Whether the delivery succeeds depends on the layout.
What they found
The researchers found several patterns linked to how well the drug worked.
First, tumors where HER2 was more spread out among the cancer cells tended to respond better. This fits with something called the bystander effect. Once the payload is released, it can reach neighboring cancer cells too, even ones with little HER2 of their own.
Second, in HER2-positive tumors, the resistant pieces looked different. They had lower activity of ERBB2, the gene that makes HER2, so there was less of the “address” for the drug to find. They also showed more activity in two growth pathways, called PI3K and EGFR. The researchers say a self-feeding growth signal involving a molecule called amphiregulin may play a part, though that is a possibility and not a proven cause.
Third, in HER2-low tumors, resistance was linked to delivery problems. The resistant pieces had cancer cells sitting farther from blood vessels. They also had less of the enzymes that cut the payload loose from the antibody (cathepsin linker-cleaving enzymes) in the same spots as HER2. The models predicted a lower concentration of the drug’s payload around those tumor areas.
Finally, in an exploratory look at paired samples, taken before treatment and after the cancer progressed, cancer cells were farther from blood vessels once resistance had appeared. Put simply, in these samples, cancer cells that sat farther from the “streets” were harder for the drug to reach.
What does this mean for treatment?
Nothing changes yet. The study did not test a new way to treat anyone. It identified features that are associated with response and resistance, and it gives researchers specific things to investigate. Those could someday include ways to spot resistance earlier or to design drugs that travel better through tumors.
For women’s cancers more broadly, the lesson is that where things sit inside a tumor can matter as much as which genes are switched on.
What you can do today
Your current advice stays the same. If you or someone close to you is being treated for breast cancer, keep following the plan your oncology team set. If this story made you curious, write down one question, such as “What do we know about why this treatment works for some people and not others?”, and bring it to your next appointment.
For clinicians and researchers
Design: Spatial transcriptomics study of clinical tumor samples from patients with HER2-positive and HER2-low metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd), comparing resistant and responsive tumor fragments. Sample size and follow-up are not given in the abstract.
Main result: More spatially dispersed HER2 expression in cancer cells correlated with improved response. HER2-positive resistance showed ERBB2 downregulation and PI3K and EGFR activation; HER2-low resistance was associated with greater cancer-to-vessel distance. No effect sizes are reported.
Main limitation: Exploratory, hypothesis-generating analyses of clinical samples; correlative associations cannot establish causation, and the longitudinal paired-sample analysis is explicitly exploratory.
Open question: Whether the candidate determinants (HER2 spatial dispersion, cancer-to-vessel distance, autocrine amphiregulin-EGFR signaling) causally drive T-DXd resistance and can guide treatment selection remains to be tested.
Cite this article
Mongevity Desk. In women’s cancers, resistance to a key breast cancer drug is linked to tumor layout. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/womens-cancers-why-breast-tumors-resist-trastuzumab-deruxtecan/Mongevity Desk. In women’s cancers, resistance to a key breast cancer drug is linked to tumor layout [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/womens-cancers-why-breast-tumors-resist-trastuzumab-deruxtecan/Mongevity Desk. (2026, November 22). In women’s cancers, resistance to a key breast cancer drug is linked to tumor layout. Mongevity. https://mongevity.science/cancer/2026/11/womens-cancers-why-breast-tumors-resist-trastuzumab-deruxtecan/
<a href="https://mongevity.science/cancer/2026/11/womens-cancers-why-breast-tumors-resist-trastuzumab-deruxtecan/">In women’s cancers, resistance to a key breast cancer drug is linked to tumor layout</a>
Free to share or quote with credit and a link.
Questions and answers
- What is trastuzumab deruxtecan (T-DXd)?
- It is a drug that attaches to a protein called HER2 on cancer cells and delivers chemotherapy directly to them. It is used for HER2-positive and HER2-low metastatic breast cancers.
- Does this study change how breast cancer is treated?
- No. It describes patterns linked to response and resistance and gives researchers ideas to test. Current treatment advice stays the same.
- What is the bystander effect?
- It means the drug's chemotherapy payload can reach nearby cancer cells, even ones with little HER2. In this study, tumors with more spread-out HER2 tended to respond better, which fits that idea.
- Why does distance from blood vessels matter?
- Blood vessels carry the drug into a tumor. In the HER2-low tumors studied, cancer cells farther from vessels were linked to resistance, and predicted drug levels around them were lower.





